

**MSAD 11
STATE OF MAINE OVERDOSE PREVENTION PROGRAM**

I. Definition

To establish a protocol for storing and distributing naloxone hydrochloride kits to individuals at risk of a drug overdose and other community-based agencies eligible to distribute to at-risk individuals, through State of Maine's Overdose Prevention Program, consistent with Maine State law. See Title 22 MRSA Chapter 556-A, Section 2353.

II. General Principles

This policy establishes that the Chief Medical Officer of MaineGeneral Medical Center will issue standing orders for naloxone hydrochloride (Naloxone) to MSAD 11, for dispensing through qualified agents capable of instructing responders in the use of naloxone. These activities are authorized by enacted legislation and standing orders of the Chief Medical Officer. It is the responsibility of MSAD 11 staff to implement this departmental policy.

III. Equipment Required

- 1) Narcan: Narcan is a self-contained nasal spray device used for the administration of one dose of naloxone hydrochloride.
- 2) Intramuscular Naloxone Injection: Injectable naloxone will include the vial of naloxone hydrochloride, two 3-ml syringes, and two 23g needles.

IV. Procedure

- 1) Standing Orders. The Chief MGH Medical Officer of MaineGeneral Medical Center will issue standing orders to the MSAD 11 for the possession, storage, dispensing, and distribution of naloxone hydrochloride and any necessary supplies for its administration. At a minimum the standing orders will contain the following information:
 - a. The name of the community-based agency that will store, dispense, and distribute the supply of naloxone hydrochloride.
 - b. Eligibility criteria to receive naloxone hydrochloride.
 - c. Delivery method and formulation of the naloxone hydrochloride, such as auto-injector, intranasal, or intramuscular.

- 2) Storage. All naloxone kits will be stored in a secured location (i.e., locked room or cabinet) with limited access to authorized individuals and at an approved storage temperature.
 - a. Intramuscular Naloxone Hydrochloride: Vials of naloxone hydrochloride shall be stored at 68-77° F and away from direct exposure to light.
 - b. Narcan (intranasal): Narcan intranasal kits shall be stored at 59-77° F.
- 3) Inventory Management. Program staff shall track the inventory of naloxone hydrochloride supply.
- 4) The program shall not charge or otherwise receive compensation for providing naloxone to community members and individuals at risk of an opioid related poisoning.
- 5) The program shall utilize criteria for determining the distribution of naloxone to individuals as stated in the Rules Governing Community-Based Drug Overdose Prevention Programs (14-118 Chapter 19). In addition, the program may develop additional criteria to facilitate distribution to high-risk populations. At a minimum:
 - a. An individual at risk of experiencing an opioid-related drug overdose.
 - b. A member of an individual's immediate family or friend of the individual.
 - c. Another person in a position to assist the individual if the individual is at risk of experiencing an opioid-related drug overdose.
- 6) Distribution Records. Program staff shall maintain a record of all naloxone hydrochloride distribution/dispensing by the programs. At a minimum, the record must include:
 - a. Name of individual/organization or de-identified mechanism to whom the naloxone was distributed.
 - b. Amount of naloxone hydrochloride distributed/dispensed.

Legal Reference: Title 22 MRSA Chapter 556-A, Section 2353

Cross Reference: JLCD – Administration of Medicine to Students

Adopted: August 17, 2023